Free Trial

Intellia Therapeutics (NTLA) News Today

Intellia Therapeutics logo
$9.66 +0.34 (+3.65%)
Closing price 04:00 PM Eastern
Extended Trading
$7.78 -1.89 (-19.51%)
As of 05:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

NTLA Latest News

Intellia Therapeutics, Inc. stock logo
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Shares Purchased by Polar Asset Management Partners Inc.
Polar Asset Management Partners Inc. boosted its holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) by 1,144.1% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 282,400 shares of the comp
Intellia Therapeutics, Inc. stock logo
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Shares Purchased by Millennium Management LLC
Millennium Management LLC raised its position in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) by 190.5% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 668,926 shares of the company
Intellia Therapeutics, Inc. stock logo
Bank of America Corp DE Trims Holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA)
Bank of America Corp DE cut its stake in Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) by 10.7% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 639,696 shares of the company's stock after selling 76,495 shares d
Intellia Therapeutics, Inc. stock logo
Intellia Therapeutics (NASDAQ:NTLA) Trading Down 4.3% - Time to Sell?
Intellia Therapeutics (NASDAQ:NTLA) Stock Price Down 4.3% - Time to Sell?
Intellia Therapeutics, Inc. stock logo
Voloridge Investment Management LLC Acquires 1,059,751 Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA)
Voloridge Investment Management LLC grew its position in Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) by 226.8% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 1,526,994 shares of the company's stock after buying an additional 1,059,751 shares dur
Intellia Therapeutics, Inc. stock logo
Two Sigma Investments LP Has $21.50 Million Position in Intellia Therapeutics, Inc. (NASDAQ:NTLA)
Two Sigma Investments LP raised its holdings in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) by 88.1% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,843,743 shares of the company's stock after purc
Intellia Therapeutics, Inc. stock logo
Deutsche Bank AG Raises Stake in Intellia Therapeutics, Inc. (NASDAQ:NTLA)
Deutsche Bank AG boosted its holdings in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) by 12.1% during the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 252,501 shares of the company's stock after purchasing an additional 27,282 shares during
Stock chart graphic
Analysts Think These Stocks Could More Than Double in Value (NTLA)
Septerna, Intellia, and Novavax have garnered investor attention for their significant upside potential, but investors should beware the risks as well.
Intellia Therapeutics, Inc. stock logo
Two Sigma Advisers LP Acquires 970,700 Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA)
Two Sigma Advisers LP boosted its stake in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) by 94.5% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 1,998,317 shares of the company's stock after buying an a
Intellia Therapeutics, Inc. stock logo
Intellia Therapeutics (NASDAQ:NTLA) Earns Buy Rating from HC Wainwright
HC Wainwright reissued a "buy" rating and issued a $30.00 price target on shares of Intellia Therapeutics in a research note on Tuesday.
Intellia Therapeutics, Inc. stock logo
Vestal Point Capital LP Makes New $6.12 Million Investment in Intellia Therapeutics, Inc. (NASDAQ:NTLA)
Vestal Point Capital LP acquired a new position in Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 525,000 shares of the company's st
Intellia Therapeutics, Inc. stock logo
Tema Etfs LLC Makes New Investment in Intellia Therapeutics, Inc. (NASDAQ:NTLA)
Tema Etfs LLC purchased a new position in Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 148,167 shares of the company's stock, valued at approximately $1,
Intellia Therapeutics, Inc. stock logo
Second Line Capital LLC Takes Position in Intellia Therapeutics, Inc. (NASDAQ:NTLA)
Second Line Capital LLC purchased a new stake in Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 131,122 shares of the co
Intellia Therapeutics, Inc. stock logo
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Shares Bought by Northern Trust Corp
Northern Trust Corp grew its holdings in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) by 13.0% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 979,137 shares of the company's stock after acquiring an additional 112,847 shares during the q
Intellia Therapeutics, Inc. stock logo
Sphera Funds Management LTD. Grows Stock Position in Intellia Therapeutics, Inc. (NASDAQ:NTLA)
Sphera Funds Management LTD. grew its position in Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) by 60.1% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 466,080 shares of th
Intellia Therapeutics, Inc. stock logo
Polar Asset Management Partners Inc. Boosts Stock Holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA)
Polar Asset Management Partners Inc. boosted its position in Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) by 1,144.1% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 282,400 shares of the company's
Intellia Therapeutics, Inc. stock logo
Patient Square Capital LP Increases Position in Intellia Therapeutics, Inc. (NASDAQ:NTLA)
Patient Square Capital LP increased its stake in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) by 68.0% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 215,981 shares
Intellia Therapeutics, Inc. stock logo
FY2025 EPS Estimates for NTLA Lifted by Cantor Fitzgerald
Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) - Cantor Fitzgerald upped their FY2025 earnings per share estimates for shares of Intellia Therapeutics in a research note issued to investors on Monday, May 12th. Cantor Fitzgerald analyst R. Bienkowski now expects that the company will ear
Intellia Therapeutics, Inc. stock logo
BNP Paribas Financial Markets Has $5.11 Million Stake in Intellia Therapeutics, Inc. (NASDAQ:NTLA)
BNP Paribas Financial Markets increased its position in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) by 78.0% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 438,458 shares of the company's s
Intellia Therapeutics, Inc. stock logo
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Holdings Decreased by Price T Rowe Associates Inc. MD
Price T Rowe Associates Inc. MD reduced its position in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) by 93.3% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 39,295 shares of th
Intellia Therapeutics, Inc. stock logo
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Shares Purchased by Hudson Bay Capital Management LP
Hudson Bay Capital Management LP boosted its stake in Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) by 52.9% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 512,300 shares of the company's st
Intellia Therapeutics, Inc. stock logo
Guggenheim Lowers Intellia Therapeutics (NASDAQ:NTLA) Price Target to $45.00
Guggenheim lowered their price objective on shares of Intellia Therapeutics from $55.00 to $45.00 and set a "buy" rating for the company in a research note on Monday.
Intellia Therapeutics, Inc. stock logo
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Given Consensus Recommendation of "Moderate Buy" by Brokerages
Intellia Therapeutics, Inc. (NASDAQ:NTLA - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the twenty research firms that are covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, six have issued a hold r
Intellia Therapeutics, Inc. stock logo
Intellia Therapeutics (NASDAQ:NTLA) Receives Buy Rating from Chardan Capital
Chardan Capital reiterated a "buy" rating and issued a $68.00 price objective on shares of Intellia Therapeutics in a research note on Friday.
Intellia Therapeutics, Inc. stock logo
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Shares Acquired by Brevan Howard Capital Management LP
Brevan Howard Capital Management LP increased its position in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) by 626.3% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned
Intellia Therapeutics, Inc. stock logo
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Position Increased by Dimensional Fund Advisors LP
Dimensional Fund Advisors LP lifted its position in Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) by 36.5% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,976,212 shares o
Intellia Therapeutics, Inc. stock logo
Capstone Investment Advisors LLC Grows Stock Position in Intellia Therapeutics, Inc. (NASDAQ:NTLA)
Capstone Investment Advisors LLC increased its position in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) by 77.8% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 108,665 shares of the company's stock after purchasing an
Intellia Therapeutics, Inc. stock logo
Aptus Capital Advisors LLC Takes $1.62 Million Position in Intellia Therapeutics, Inc. (NASDAQ:NTLA)
Aptus Capital Advisors LLC acquired a new position in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 139,278 shares of the company's stock, valued at approximately $1,624
Intellia Therapeutics, Inc. stock logo
Baker BROS. Advisors LP Purchases New Shares in Intellia Therapeutics, Inc. (NASDAQ:NTLA)
Baker BROS. Advisors LP bought a new stake in Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 644,116 shares of the company's stock, valued at a
Intellia Therapeutics, Inc. stock logo
Intellia Therapeutics (NTLA) Expected to Announce Earnings on Thursday
Intellia Therapeutics (NASDAQ:NTLA) will be releasing its Q1 2025 earnings before the market opens on Thursday, May 8. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-8-intellia-therapeutics-inc-stock/)
Intellia Therapeutics, Inc. stock logo
Stifel Financial Corp Buys 303,151 Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA)
Stifel Financial Corp raised its stake in Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) by 320.4% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 397,761 shares of the company's
Get Intellia Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for NTLA and its competitors with MarketBeat's FREE daily newsletter.

NTLA Media Mentions By Week

NTLA Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

NTLA
News Sentiment

1.02

1.03

Average
Medical
News Sentiment

NTLA News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

NTLA Articles
This Week

13

12

NTLA Articles
Average Week

Get Intellia Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for NTLA and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools


This page (NASDAQ:NTLA) was last updated on 5/28/2025 by MarketBeat.com Staff
From Our Partners